Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.

MLA

Lasagna, A., et al. “Analysis of the Humoral and Cellular Immune Response after a Full Course of BNT162b2 Anti-SARS-CoV-2 Vaccine in Cancer Patients Treated with PD-1/PD-L1 Inhibitors with or without Chemotherapy: An Update after 6 Months of Follow-Up.” ESMO Open, vol. 7, no. 1, Feb. 2022, p. 100359. EBSCOhost, https://doi.org/10.1016/j.esmoop.2021.100359.

APA

Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J. C., Ferrari, A., Zavaglio, F., Arena, F., Secondino, S., Falzoni, M., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., … Cassaniti, I. (2022). Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up. ESMO Open, 7(1), 100359. https://doi.org/10.1016/j.esmoop.2021.100359

Chicago

Lasagna, A, D Lilleri, F Agustoni, E Percivalle, S Borgetto, N Alessio, G Comolli, et al. 2022. “Analysis of the Humoral and Cellular Immune Response after a Full Course of BNT162b2 Anti-SARS-CoV-2 Vaccine in Cancer Patients Treated with PD-1/PD-L1 Inhibitors with or without Chemotherapy: An Update after 6 Months of Follow-Up.” ESMO Open 7 (1): 100359. doi:10.1016/j.esmoop.2021.100359.